about
Potential use of rapamycin in HIV infectionCurrent perspectives on HIV-1 antiretroviral drug resistanceEvidence and controversies on the role of XMRV in prostate cancer and chronic fatigue syndromeTransmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development.Combinatorial approaches to the prevention and treatment of HIV-1 infectionCNS demyelinating disorder with mixed features of neuromyelitis optica and multiple sclerosis in HIV-1 infection. Case report and literature review.Clinical Improvement by Switching to an Integrase Strand Transfer Inhibitor in Hemophiliac Patients with HIV: The Japan Cohort Study of HIV Patients Infected through Blood ProductsSimilar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients.Evaluation of a system to screen for stimulators of non-specific DNA nicking by HIV-1 integrase: application to a library of 50,000 compounds.Antiretroviral therapy: current drugsElvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor.Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment.Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study.Effect of ginkgo biloba on the pharmacokinetics of raltegravir in healthy volunteersLong-term immunologic and virologic responses on raltegravir-containing regimens among ART-experienced participants in the HIV Outpatient Study.Multiple genetic pathways involving amino acid position 143 of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvitegravir.Treatment with suboptimal doses of raltegravir leads to aberrant HIV-1 integrations.Pharmacotherapy of pediatric and adolescent HIV infectionDrug resistant integrase mutants cause aberrant HIV integrations.Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc.A review of the toxicity of HIV medications.The use of integrase inhibitors in treatment-experienced patients.Chelation Motifs Affecting Metal-dependent Viral Enzymes: N'-acylhydrazone Ligands as Dual Target Inhibitors of HIV-1 Integrase and Reverse Transcriptase Ribonuclease H DomainApproaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients.Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics.Antiretroviral therapy 2010 update: current practices and controversies.Combination dolutegravir-abacavir-lamivudine in the management of HIV/AIDS: clinical utility and patient considerations.Longitudinal analysis of integrase N155H variants in heavily treated patients failing raltegravir-based regimens.Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients.Ageing with HIV: do comorbidities and polymedication drive treatment optimization?Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors.Review on the Biological Mechanisms Associated with Depo-Provera and HIV-1 Risk Acquisition in Women.Isolation and anti-HIV-1 integrase activity of lentzeosides A-F from extremotolerant lentzea sp. H45, a strain isolated from a high-altitude Atacama Desert soil.HIV Tat induces a prolonged MYC relocalization next to IGH in circulating B-cells.Covalent Inhibition of HIV-1 Integrase by N-Succinimidyl Peptides.Raltegravir monohydrate.Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir.Deciphering the impact of parameters influencing transgene expression kinetics after repeated cell transduction with integration-deficient retroviral vectors.
P2860
Q24606795-E429E015-0127-4D47-86C9-4BCCD57150BCQ26852626-246D6AA3-C35D-47C1-BABF-5BBB6318C364Q28304673-41A4DDD3-098B-4F23-9EAB-31714F95E257Q28476489-2B2B18C0-D4F7-4E8B-9C5D-C4027537C36DQ30381745-051CD58B-FF4C-4349-AFE2-60BF2B3170BEQ30400060-7B771FD3-8B23-43BD-976E-328F0AE92916Q30834276-073BE3CD-F09D-412D-BBE0-2C6BA4416ADDQ33668385-23AE5970-2813-4B57-88BE-48EE05336297Q33935930-99C1B79A-1037-4716-BFB2-8F2CBA62E462Q34044741-5C11B506-66E6-45B2-8C64-CC8923B96249Q34085926-E958B9B7-444F-4100-8B7C-23E509201E99Q34634156-08322DA6-AFBA-469E-9C08-120A3510EC15Q34737411-092E07E5-740D-4726-B603-F7074AEA04C8Q35974422-B0E28DA6-3440-4AE8-BAC7-FD6D00AFF965Q36250418-E0E2D5EF-2421-431B-8B4A-34BE0F21C54EQ36276907-43CAB50E-D814-4F24-8B31-EDF934B3A52EQ36311771-A88E6008-AB75-47C9-8234-12C3D5C3218AQ37124155-B288114B-DFAC-4965-8452-278755B14DBCQ37157254-FC39608A-B47D-4E29-B081-9932FFE8EB94Q37240305-4F7F6941-0AD8-4A2E-9EEC-E1C8258C9219Q37294690-3E86D152-9594-4535-BCED-CD08F609DD0CQ37452124-7A2DBA0C-372A-420B-8A23-3E6C7F0AFFEEQ37633495-B681FA75-1AA2-4E17-A84B-60B47159CE07Q37644122-C2404710-7604-4888-B4BD-CA0EB1B97CE5Q37710343-0171EAAB-CEE1-4445-9AFD-3CA2272A4E38Q37845854-F7692D36-34C5-4472-9BF5-807F8C734D75Q37866298-D8B6B13E-9CC6-4CA5-96AC-4238E6D51C7DQ37910819-69664B41-8C09-46FD-A145-9E6FE8A68A5CQ38367106-BBB391C4-BCF3-4CC7-AA4F-0A11D1E8B172Q38400895-BB450918-E444-4E03-BFBB-433655F56E42Q38954109-7F21A911-A64E-4AB0-9D4E-807844ACD474Q38958705-E67073BB-DCBD-472F-A3EF-830F30CE68C8Q39006806-9C143293-11BA-4ACF-9FD2-6849882CA3B5Q39347553-482CB5E4-7A92-4FB6-9401-37F83EB615FBQ39591309-E29A4DA2-2FB5-4A2C-A410-B552F113C7EAQ40271342-11DAC9A2-1D4A-415F-BBD7-F869B25A6D4BQ40688076-5DFF8688-3CF2-4772-8DDE-1FB7EC67E8BDQ41831368-E0705E5F-7FE8-42E4-8228-0AAE9C79F1D1Q41965052-BA17F03B-9B28-4663-BD30-35183305A61AQ42158445-921FFA23-2EB9-4772-8180-9F12C0156A3B
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Raltegravir: the first HIV type 1 integrase inhibitor
@ast
Raltegravir: the first HIV type 1 integrase inhibitor
@en
Raltegravir: the first HIV type 1 integrase inhibitor
@nl
type
label
Raltegravir: the first HIV type 1 integrase inhibitor
@ast
Raltegravir: the first HIV type 1 integrase inhibitor
@en
Raltegravir: the first HIV type 1 integrase inhibitor
@nl
prefLabel
Raltegravir: the first HIV type 1 integrase inhibitor
@ast
Raltegravir: the first HIV type 1 integrase inhibitor
@en
Raltegravir: the first HIV type 1 integrase inhibitor
@nl
P3181
P356
P1476
Raltegravir: the first HIV type 1 integrase inhibitor
@en
P2093
Charles Hicks
Roy M Gulick
P3181
P356
10.1086/597290
P407
P577
2009-04-01T00:00:00Z